Back to Search
Start Over
Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 and ANGPTL3 (Angiopoietin-Like Protein 3)
- Source :
- Arteriosclerosis, thrombosis, and vascular biology.
- Publication Year :
- 2022
-
Abstract
- The positive relationship between increased levels of circulating triglycerides and cardiovascular events has been observed for decades. Driven by genetic cohort studies, inhibitors of APOC3 and ANGPTL (angiopoietin-like protein) 3 that reduce circulating triglycerides are poised to enter clinical practice. We will review the biology of how inhibition of these 2 proteins affects circulating lipoproteins as well as the current state of clinical development of monoclonal antibodies, antisense oligonucleotides, and silencing RNAs targeting APOC3 and ANGPTL3.
Details
- ISSN :
- 15244636
- Database :
- OpenAIRE
- Journal :
- Arteriosclerosis, thrombosis, and vascular biology
- Accession number :
- edsair.pmid..........136b340185d738ccd34cfa5f1064247b